Hindustan Antibiotics proposal to reduce China dependence for APIs

5 March 2020

As the Indian government scouts for options to deal with any potential active pharmaceutical ingredient (API) scarcity that can arise in the future to counter the new coronavirus (COVID-19), the country's oldest public sector pharmaceutical company, Hindustan Antibiotics Limited (HAL), has submitted a proposal to the government to reduce dependence on China for fermentation-based bulk drugs.

Other public sector undertakings (PSU) have also offered to step in to reduce API drug dependence from China, reports The Pharma Letter’s local correspondent.

HAL's proposal says it can make up to 50% of the bulk drugs if it is provided financial assistance to upgrade its infrastructure.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK